Penn Center for Myeloproliferative Neoplasms

Research & Clinical Trials

Penn's Abramson Cancer Center, a National Cancer Institute-designated comprehensive cancer center, oversees one of the largest clinical trial programs in the country, with more than 200 trials available at any one time.  Part of the Abramson Cancer Center, the Penn Center for Myeloproliferative Neoplasms allows access to clinical trials with novel agents designed specifically for patients with MPN. 

Abramson Cancer Center Clinical Trial Information Service

Current MPN Clinical Trials

• Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
• Study of DISC-0974 in Participants With Myelofibrosis and Anemia
• A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Penn Stem Cell and Xenograft Core (SCXC)

Penn Stem Cell and Xenograft Core (SCXC) is a comprehensive resource laboratory that integrates a viable tissue bank of normal human hematopoietic cells and hematopoietic malignancies with a full range of xenograft services. The SCXC is committed to facilitating and promoting translational research involving primary human hematopoietic tissues, and boasts a large repository of samples from patients with myeloproliferative neoplasms. All samples are fully annotated and frozen as viable cells, with expert consultative services in primary human hematopoietic stem/progenitor and leukemic cell culture and manipulation is available.